Vaccine Info

Shingles Vaccines 2023

Authored by
Staff
Last reviewed
January 10, 2023
Fact checked by
Robert Carlson, MD
Share

Shingles Vaccines For 2023

Shingles (Herpes Zoster) is a vaccine-preventable disease caused by the varicella-zoster virus (VZV), known as shingles, the same virus that causes chickenpox, says the U.S. Centers for Disease Control and Prevention (CDC). The CDC published updated vaccination schedules for 2022

As of January 10, 2023, there are U.S. Food and Drug Administration (FDA)-approved shingles vaccines for use in the U.S. And Immuinize.org publishes updated FAQs regarding shingles vaccines.

Shingles Vaccines Approved

Shingrix - GSK's Shingrix is a non-live, adjuvanted recombinant shingles vaccine (zoster) consisting of the varicella-zoster virus glycoprotein E antigen and the AS01B adjuvant system, a proprietary adjuvant containing QS-21 and MPL with liposomes.

Zostavax - Merck's Zostavax is a live, attenuated varicella-zoster virus (weakened chickenpox virus) vaccine. According to the U.S. CDC, the zoster vaccine can be administered concurrently with all other live and inactivated vaccines, including those routinely recommended for people 60 years or older, such as influenza and pneumococcal vaccines.

SK bioscience's SKYZoster™ is a live vaccine that attenuates the varicella-zoster virus. SKYZoster was approved in South Korea by the Ministry of Food and Drug Safety in September 2017. It is also approved in Malaysia and Thailand. SK bioscience plans to submit SKYZoster™ for WHO Pre-Qualification.

Shingles Vaccine Candidates for 2023

Curevo Vaccine's CRV-101 is an adjuvanted subunit shingles vaccine candidate designed to maximize CMI protection by combining the gE protein antigen with our proprietary adjuvant. CRV-101 was specifically designed to produce an optimal immune response using a smaller amount of adjuvant but with fewer side effects than the currently-approved shingles vaccine. 

Pfizer and BioNTech are developing an mRNA vaccine for shingles. Clinical trials are planned to start in the second half of 2022

Jiangsu Recbio Technology Co., Ltd. announced on December 19, 2022, that it received approval from the Philippines FDA to conduct a randomized, observer-blinded, GSK Shingrix® active-controlled phase I clinical trial to evaluate the safety and immunogenicity of REC610 in healthy adult subjects aged 40 and above. REC610 is equipped with a new adjuvant BFA01 independently developed by the company, which can promote the production of high levels of VZV glycoprotein E (gE)-specific CD4+ T cells and antibodies. 

Immorna announced on January 9. 2023, that the U.S. FDA cleared its investigational new drug application to conduct a Phase 1 multi-center study of JCXH-105, a self-replicating RNA vaccine against Shingles (Herpes Zoster). 

Shingles Vaccine Price

Most patients pay an out-of-pocket cost of about $50 per dose with insurance. The U.S. CDC Vaccine Price List was last updated in July 2022. As of January 2023, vaccinations covered under Medicare part D, approved and recommended by the CDC, will be covered without a co-pay.

And vaccine prices and discount information are posted at InstantRx™.

Shingles Vaccine News For 2019 - 2023

January 9, 2023 - SK bioscience announced that the company has received a biologics license application approval of the SKYZoster™ from the National Pharmaceutical Regulatory Agency in Malaysia.

November 26, 2022 - Willingness to accept herpes zoster vaccines and the influencing factors in China.

November 16, 2022 - "Completing this ($26 million) A1 round ahead of data from our Phase 2b trial of CRV-101 head-to-head against Shingrix® is a meaningful demonstration of the confidence our investors have in the CRV-101 program," said George Simeon, Curevo's CEO. 

September 15, 2022 - Curevo Vaccine announced the completion of enrollment in a Phase 2b trial of their CRV-101 subunit vaccine to prevent the reactivation of the varicella-zoster virus (shingles) in older adults.

August 2, 2022 - Tufts University and The University of Oxford researchers demonstrated the presence of two viruses that promote excess proteins responsible for Alzheimer's characteristic brain plaques. Study Conclusion: Our results are consistent with the suggestion that shingles cause the reactivation of HSV1 in the brain. The reactivating HSV1 was probably through inflammation, the researchers reported.

June 1, 2022 - The Journal of Infectious Diseases published research that evaluated the association between recombinant, adjuvanted zoster vaccine COVID-19 outcomes at Kaiser Permanente Southern California. It concluded that RZV vaccination was associated with a 16% lower risk of COVID-19 diagnosis and a 32% lower risk of hospitalization. 

April 3, 2022 - A retrospective cohort study found adults (50 yrs+) with COVID-19 had a 15% increased risk of developing herpes zoster.

April 1, 2022 - Aurobindo Pharma Limited received final approval from U.S. FDA for its Abbreviated New Drug Application, Acyclovir Oral Suspension USP, 200 mg/5 mL. Aurobindo Pharma's Acyclovir Oral Suspension, an AB-rated generic equivalent to the reference listed drug (RLD), ZOVIRAX ® (acyclovir), of Mylan Pharmaceuticals Inc. Acyclovir Oral Suspension is indicated for: Acute treatment of herpes zoster (shingles), Treatment of initial episodes and the management of recurrent episodes of genital herpes, and the treatment of chickenpox (varicella).

March 25, 2022 - Consumer Reports published an article: The Booster Shots You Need As an Adult. The shingles vaccine isn't commonly referred to as a booster, but it does count as one because it reminds your body how to fight the varicella-zoster virus.

March 14, 2022 - GreenLight Biosciences Holdings PBC announced a licensing agreement with Serum Institute of India, Pvt, Ltd., to accelerate access to messenger RNA products (Shingles) in emerging markets.

March 10, 2022 - The U.S. FDA confirmed that GSK completed its recall of 130,000 doses of Shingrix.

March 3, 2022 - Are You Aware of Your Shingles Risk?

February 28, 2022 - GSK launched the inaugural Shingles Awareness Week to educate the general public about shingles in collaboration with the International Federation on Ageing.

February 25, 2022 - GSK wrote the mysterious reactivation (of VZV) that a doctor studied for the first time in Cirencester, England, more than half a century ago. By tracking 1,270 patients from 1947 to 1962, R. Edgar Hope-Simpson demonstrated that shingles were not a new infection from an unknown pathogen but rather a reawakening of the VZV.

July 14, 2020 - Shingles Vaccination Rates Significantly Increased With Seniors.

February 13, 2020 - Shingles Vaccination Reduced Stroke Risk By 16%.

September 26, 2019 - Curevo, Inc. announced encouraging preliminary Phase I study results of their Shingles vaccine candidate, CRV-101. 

May 23, 2019 - GlaxoSmithKline plc announced that China's National Medical Products Administration approved Shingrix to prevent shingles in adults aged 50 years or older.

 

Note: This page aggregates and edits content for clarity and was manually curated for mobile readers.

Clinical Trials

No clinical trials found